Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Regulatory Peptides|November 20, 2012
Glucagon-like peptide-2 stimulates mucosal microcirculation measured by laser Doppler flowmetry in end-jejunostomy short bowel syndrome patientsP Høyerup, P M Hellström, P T Schmidt, et al.
European Journal of Clinical Nutrition|July 26, 2012
Randomised controlled trial of colostrum to improve intestinal function in patients with short bowel syndromeP Lund, P T Sangild, L Aunsholt, et al.
Metabolism: Clinical and Experimental|March 21, 2003
Antihyperglycemic and blood pressure-reducing effects of stevioside in the diabetic Goto-Kakizaki ratP B Jeppesen, S Gregersen, S E D Rolfsen, et al.
Regulatory Peptides|March 21, 2013
Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled studyK B Madsen, C Askov-Hansen, R M Naimi, et al.
Regulatory Peptides|March 19, 2013
A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patientsR M Naimi, K B Madsen, C Askov-Hansen, et al.
Clinical Nutrition (Edinburgh, Scotland)|January 1, 2013
Development and validation of the disease-specific Short Bowel Syndrome-Quality of Life (SBS-QoL™) scaleP Berghöfer, K C Fragkos, J P Baxter, et al.
Gastroenterology Research and Practice|July 11, 2009
Short bowel patients treated for two years with glucagon-like peptide 2 (GLP-2): compliance, safety, and effects on quality of lifeP B Jeppesen, P Lund, I B Gottschalck, et al.
Gastroenterology Research and Practice|August 27, 2009
Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle functionP B Jeppesen, P Lund, I B Gottschalck, et al.
Alimentary Pharmacology & Therapeutics|July 7, 2018
Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutritionY Wouters, M Theilla, P Singer, et al.
Clinical Nutrition (Edinburgh, Scotland)|April 17, 2013
Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled studyP B Jeppesen, M Pertkiewicz, A Forbes, et al.
Pageof 6